MIST:NASDAQ, Milestone Pharmaceuticals Inc.
Why MIST stock fell on November 16
Milestone Pharmaceuticals Inc. fell 29.8%
on Monday, November 16, 2026, on 8,721,818 shares, 5.9 times its average daily volume.
No headline about MIST came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
MIST stock overview
Milestone Pharmaceuticals Inc. (MIST:NASDAQ) closed at $0.422 on November 17, 2026,
up 15.59% on the day.
The stock trades 86.2% below its 52-week high of $3.06
and 16.5% above its 52-week low of $0.362.
Over the past year, it lost 84.3%.
Milestone Pharmaceuticals Inc. is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $0.422
- Day change
- +15.59%
- Volume
- 4,090,285
- Average volume
- 1,486,557
- Market cap
- 52M+
- 52-week range
- $0.362 – $3.06
- 50-day average
- $0.785
- 200-day average
- $1.30
Price action over the past year
In 252 trading sessions since November 14, 2025, MIST closed higher on 102 days (40%).
Its best day was March 31, 2026 (+17.82%) and its worst was November 16, 2026 (-29.81%).
The stock moved 10% or more in a single session 18 times.
Recent signals
MIST news
-
Nov 17, 2026:
Milestone Pharmaceuticals (MIST) Stock Sees Fair Value Cut As Cardamyst Launch Concerns Persist
-
Nov 13, 2026:
Milestone Pharmaceuticals Inc. Q3 2026 Earnings Call Summary
-
Nov 13, 2026:
Milestone Pharmaceuticals Q3 Earnings Call Highlights
-
Nov 13, 2026:
Milestone Pharmaceuticals Beats On A One-Time License Payment, But A 30% Cost Cut Shows The CARDAMYST Launch Is Running Below Plan
-
Nov 13, 2026:
Why Is Milestone Pharmaceuticals Stock Rising 6% Following Its Third-Quarter Results?
-
Nov 13, 2026:
Milestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through AFib-RVR Phase 3 Data
-
Nov 13, 2026:
Milestone Pharmaceuticals (MIST) Reports Q3 Loss, Beats Revenue Estimates
-
Nov 13, 2026:
Milestone Pharmaceuticals: Q3 Earnings Snapshot
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications.
Similar stocks
Find more stocks like MIST with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.